Traws Pharma (NASDAQ:TRAW – Get Free Report) posted its earnings results on Monday. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03, Zacks reports.
Traws Pharma Price Performance
NASDAQ TRAW traded up $0.01 during trading hours on Monday, reaching $0.26. 210,244 shares of the stock traded hands, compared to its average volume of 915,880. The stock has a 50 day simple moving average of $0.43 and a two-hundred day simple moving average of $1.07. Traws Pharma has a 1 year low of $0.22 and a 1 year high of $3.23. The company has a market cap of $4.00 million, a price-to-earnings ratio of -0.15 and a beta of 1.67.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on TRAW. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective on shares of Traws Pharma in a research report on Tuesday, August 18th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $1.00.
View Our Latest Analysis on Traws Pharma
Traws Pharma Company Profile
Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.
Read More
- Five stocks we like better than Traws Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
